MedTrace Logo

QUANTACT : Impact of Pangenomic QUANTitative Alterations in Cancer Therapy

NCT04762862 · Status: ENROLLING_BY_INVITATION · Type: OBSERVATIONAL · Enrollment: 1200

Last updated 2025-04-10

No results posted yet for this study

Summary

"Precision medicine and targeted therapies have played a crucial role over the past ten years in the personalized care of cancer patients. In this retrospective and observational study, we focused on patients for which no standard or curative treatment was available and for which the management was discussed in a Molecular Tumor Board (MTB).

The role of the MTB is to decide the most appropriate therapeutic options for patients according to the potential identification of molecular targets.

Among the analyses carried out, we focused on a quantitative genome-wide analysis: the CGH/SNP-array (Comparative Genomic Hybridization / Single Nucleotide Polymorphism on array). The objective was to evaluate the impact of CGH/SNP-array analyses in the identification of targeted molecular alterations.

"

Conditions

Sponsors & Collaborators

  • Centre Antoine Lacassagne

    collaborator OTHER

  • Centre Hospitalier Universitaire de Nice

    lead OTHER

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-02-01
Primary Completion
2026-08-31
Completion
2026-12-31

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04762862 on ClinicalTrials.gov